GL1X · GenesisL1 explorer

Research workbench

X-ray crystallographic structure of ctx-M-9 beta-lactamase complexed with a boronic acid inhibitor (SM2)

Analyse X-ray crystallographic structure of ctx-M-9 beta-lactamase complexed with a… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1YM1
Type
protein
Length
523 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Beta-lactamase ctx-M-9A
EC
3.5.2.6
UniProt
Q9L5C8
Ligands
SM2, PO4
Pockets
2 · best druggability 0.29

Structure

x-ray diffraction · 2 distinct chains · 44% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABeta-lactamase ctx-M-9A (EC 3.5.2.6)protein26344% helix, 19% strandQ9L5C8
BBeta-lactamase ctx-M-9A (EC 3.5.2.6)protein26044% helix, 20% strandQ9L5C8

Ligands and binding sites

  • SM2 · (1R)-1-(2-thienylacetylamino)-1-(3-carboxyphenyl) methylboronic acid · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1560.290.7619PO4, SM2
2580.290.7517PO4, SM2

Interfaces

1 interface between chains.

  • A–B · 157 Ų buried · 3 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 1YM1 · X-ray crystallographic structure of CTX-M-9 beta-lactamase complexed with a boronic acid… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.